1. Articles from ncbi.nlm.nih.gov

  2. 73-96 of 1715 « 1 2 3 4 5 6 7 ... 70 71 72 »
    1. Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

      Surgery. 2018 May 09;:

      Authors: Subramanian C, White PT, Kuai R, Kalidindi A, Castle VP, Moon JJ, Timmermann BN, Schwendeman A, Cohen MS

      Read Full Article
      Mentions: Surgery
    2. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.

      BMC Cancer. 2018 May 11;18(1):560

      Authors: Kunnimalaiyaan S, Schwartz VK, Jackson IA, Clark Gamblin T, Kunnimalaiyaan M

      Abstract BACKGROUND: Neuroblastoma (NB) is a devastating disease. Despite recent advances in the treatment of NB, about 60% of high-risk NB will have relapse and therefore long-term event free survival is very minimal.

      Read Full Article
    3. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.

      Oncol Rep. 2018 May 08;:

      Authors: Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G, Song L

      Read Full Article
      Mentions: Chemotherapy
    4. Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Mol Med Rep. 2018 May 02;:

      Authors: Mei Z, Yan P, Wang Y, Liu S, He F

      Abstract Neuroblastoma is one of the leading causes of cancer‑associated mortality worldwide, particularly in children, partially due to the absence of effective therapeutic targets and diagnostic biomarkers.

      Read Full Article
    5. NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived Sk‑n‑as cells via the activation of β1 integrin expression.

      NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived SK‑N‑AS cells via the activation of β1 integrin expression.

      Int J Oncol. 2018 May 07;:

      Authors: Ishizuka Y, Koshinaga T, Hirano T, Nagasaki-Maeoka E, Watanabe Y, Hoshi R, Yoshizawa S, Sugito K, Kawashima H, Uekusa S, Fukuda N, Soma M, Fujiwara K

      Read Full Article
    6. Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.

      Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.

      Mol Med Rep. 2018 May 03;:

      Authors: Wang Y, Gao S, Wang W, Xia Y, Liang J

      Abstract Neuroblastoma, one of the most common types of cancer in childhood, is commonly treated with surgery, radiation and chemotherapy. However, prognosis and survival remain poor for children with high‑risk neuroblastoma. Therefore, the identification of novel, effective therapeutic targets is necessary.

      Read Full Article
    7. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.

      Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.

      Pediatr Hematol Oncol. 2018 May 08;:1-10

      Authors: Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB

      Read Full Article
      Mentions: MYCN NSE
    8. Predicting neuroblastoma using developmental signals and a logic-based model.

      Predicting neuroblastoma using developmental signals and a logic-based model.

      Biophys Chem. 2018 Apr 30;238:30-38

      Authors: Kasemeier-Kulesa JC, Schnell S, Woolley T, Spengler JA, Morrison JA, McKinney MC, Pushel I, Wolfe LA, Kulesa PM

      Abstract Genomic information from human patient samples of pediatric neuroblastoma cancers and known outcomes have led to specific gene lists put forward as high risk for disease progression.

      Read Full Article
    9. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    10. miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      Oncotarget. 2018 Apr 10;9(27):19014-19025

      Authors: Stigliani S, Morandi F, Persico L, Lagazio C, Erminio G, Scaruffi P, Corrias MV

      Read Full Article
      Mentions: Bone Marrow
    11. Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report.

      Usefulness of fluorodeoxyglucose positron emission tomography/computed tomography for detection of a neuroblastic nodule in a ganglioneuroblastoma: a case report.

      J Med Case Rep. 2018 May 03;12(1):119

      Authors: Takeda Y, Sano H, Kawano A, Mochizuki K, Takahashi N, Kobayashi S, Ohara Y, Tasaki K, Hosoya M, Kikuta A

      Read Full Article
      Mentions: MYCN
    12. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN.

      Oncotarget. 2018 Apr 06;9(26):18160-18179

      Authors: Roth SA, Hald ØH, Fuchs S, Løkke C, Mikkola I, Flægstad T, Schulte J, Einvik C

      Abstract Neuroblastoma is the most common diagnosed tumor in infants and the second most common extracranial tumor of childhood. The survival rate of patients with high-risk neuroblastoma is still very low despite intensive multimodal treatments.

      Read Full Article
      Mentions: MYCN
    13. The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.

      The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma.

      Bioelectromagnetics. 2018 May 02;:

      Authors: Yuan LQ, Wang C, Zhu K, Li HM, Gu WZ, Zhou DM, Lai JQ, Zhou D, Lv Y, Tofani S, Chen X

      Abstract Certain magnetic fields (MF) have potential therapeutic antitumor effect whereas the underlying mechanism remains undefined.

      Read Full Article
    14. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.

      PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.

      BMC Cancer. 2018 May 02;18(1):499

      Authors: Wu DD, Gao YR, Li T, Wang DY, Lu D, Liu SY, Hong Y, Ning HB, Liu JP, Shang J, Shi JF, Wei JS, Ji XY

      Read Full Article
    15. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.

      Cancer Cell Int. 2018;18:63

      Authors: Aveic S, Pantile M, Polo P, Sidarovich V, De Mariano M, Quattrone A, Longo L, Tonini GP

      Abstract Background: A growing field of evidence suggests the involvement of oncogenic receptor tyrosine kinases (RTKs) in cell transformation.

      Read Full Article
    16. Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method.

      Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method.

      Clin Chem Lab Med. 2018 May 01;:

      Authors: Grouzmann E, Centeno C, Eugster PJ

      Read Full Article
    17. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    18. Targeting of epigenetic regulators in neuroblastoma.

      Targeting of epigenetic regulators in neuroblastoma.

      Exp Mol Med. 2018 Apr 27;50(4):51

      Authors: Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF

      Abstract Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8-10% corresponding to neuroblastoma, a rare disease with an incidence of 8-9 cases per million children <15 years of age.

      Read Full Article
    19. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    20. Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.

      Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma.

      Cancer Genomics Proteomics. 2018 May-Jun;15(3):165-174

      Authors: Saeki N, Saito A, Sugaya Y, Amemiya M, Ono H, Komatsuzaki R, Yanagihara K, Sasaki H

      Read Full Article
      Mentions: Genetics
    21. Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome.

      Pediatr Blood Cancer. 2018 Apr 25;:e27110

      Authors: Johnston DL, Murray S, Irwin MS, Doyle J, Schechter T

      Abstract Opsoclonus, myoclonus, ataxia syndrome (OMA) is a severe neurologic disorder often associated with neuroblastoma. It is challenging to treat and can have long-term neurologic sequelae.

      Read Full Article
      Mentions: Refractory
    22. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      Cell Death Dis. 2018 Apr 24;9(5):458

      Authors: Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, Køhler JB, Kjellström S, Lasorsa VA, Capasso M, Fu H, Massoumi R

      Abstract BRCA1-associated protein 1 (BAP1) is a nuclear deubiquitinating enzyme that is associated with multiprotein complexes that regulate key cellular pathways, including cell cycle, cellular differentiation, cell death, and the DNA damage response.

      Read Full Article
    23. Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

      Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

      J Pediatr Hematol Oncol. 2018 Apr 20;:

      Authors: Fassel H, Bussel JB, Roberts SS, Modak S

      Abstract Thrombocytopenia, a serious complication of myelosuppressive chemotherapy in cancer patients, is managed with platelet transfusions until recovery of platelet counts. However, children receiving chemotherapy can rarely develop immune thrombocytopenia (ITP) that is refractory to transfused platelets.

      Read Full Article
    24. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Biomed Res Int. 2018;2018:1812535

      Authors: Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood with 5-year survival rate of 40% in high-risk patients despite intensive therapies.

      Read Full Article
      Mentions: Immunotherapy
    73-96 of 1715 « 1 2 3 4 5 6 7 ... 70 71 72 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video